Cite
HARVARD Citation
Motzer, R. et al. (2022). Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet oncology. 23 (6), pp. 768-780. [Online].